PT-141 Side Effects: Nausea, Flushing, Blood Pressure and More

The short version

If you read one thing about PT-141 side effects, read this. The most common problem is nausea — roughly 40% of people in long-term use felt it, and it was the top reason people quit. Flushing (a warm, red feeling) hit about 1 in 5; headache about 1 in 8. The drug briefly raises blood pressure, so it is not for anyone with uncontrolled high blood pressure or heart disease. Repeated frequent use can darken skin, gums, or freckles. The numbers below come from the trials and the label; a separate, clearly-marked section at the end carries unverified community reports.

The cited tolerability profile

These are the documented adverse events, straight from the trials and the FDA label. In the 52-week open-label extension of RECONNECT, the most common drug-related treatment-emergent adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) ^[4]. Nausea was the principal tolerability issue and a notable driver of discontinuation ^[4]. In the Phase 3 trials themselves, nausea, flushing, and headache were again the leading adverse events ^[3]. Injection-site reactions and nasal congestion are also documented in the label ^[6].

Nausea, in short, defines the tolerability of this drug: not dangerous, but common enough and unpleasant enough that it is the main reason people stop. Injection timing and dose strategy have been studied as ways to blunt it ^[3][6].

The blood-pressure signal and the contraindication

PT-141 transiently raises blood pressure and lowers heart rate after each dose — a documented, reversible cardiovascular signal characterized in ambulatory blood-pressure substudies ^[6]. Because of it, the US prescribing information contraindicates bremelanotide in people with uncontrolled hypertension or known cardiovascular disease ^[6]. This is the most safety-relevant item on the page: it is the line in the label that excludes a specific population outright, and it is a direct consequence of the melanocortin mechanism acting on more than sexual circuits. The cardiovascular reach follows directly from how PT-141 works — a melanocortin receptor agonist acts on more than the sexual-desire circuits alone.

Hyperpigmentation and the liver signal

Two slower-developing effects round out the cited profile. Focal hyperpigmentation — darkening of the face, gums, or breasts — is reported with repeated, frequent dosing and is attributed to MC1R activation in the skin, an off-target reach of a melanocortin agonist ^[6][12]. It is more associated with high-frequency use than with the as-needed label schedule.

Separately, the NIH LiverTox monograph notes that bremelanotide, a parenterally administered melanocortin agonist for female HSDD, is associated with mild serum enzyme elevations and rare instances of clinically apparent acute liver injury; it is metabolized by amide-bond hydrolysis and has minimal drug-drug interactions ^[12]. Both are part of the honest record, neither is the headline number — nausea remains that.

What the discontinuation data tells you

The most useful tolerability fact is not any single rate — it is which side effect made people stop. Across the long-term extension, nausea was the leading reason participants discontinued, even though no new safety signals emerged over 52 weeks ^[4]. That pattern — a drug that is broadly safe but frequently nauseating — is the practical shape of PT-141's tolerability. It explains why the research conversation around this molecule is less about danger and more about whether the modest benefit ^[3] is worth the nausea, a tradeoff the published re-analyses have weighed explicitly ^[3].

Field reports (not clinical data)

This section is different from everything above. The following are unverified user/community reports — reported experiences, not evidence and not advice. Nothing here is attributable to a journal, a PMID, or a measurement, and no quote or number is invented from data.

What researchers commonly report online: nausea that comes on fast — often within the first hour — and then eases; a warm "flush" sensation early after dosing; and, with the flushing, a sense that the effect is real and quick. Many describe the experience as affecting desire or spontaneous interest rather than mechanical function. Off-label male use is widely discussed. A recurring community caution is transient darkening of skin or freckles with repeated use — passed around as a warning, not a finding. Again: this is forum talk, not clinical data. For the part backed by studies, stay with the cited sections above.